Literature DB >> 18666905

The effects of cannabis abuse on the symptoms of schizophrenia: patient perspectives.

William F Costain1.   

Abstract

This study explored explanatory models used by individuals with schizophrenia in relation to continuing cannabis abuse. Cannabis is known to exacerbate positive symptoms, compound the effects of negative symptoms, and lead to relapse, having a negative effect upon quality of life. If this is so, why would people choose to continue the drug use? Most previous studies exploring this phenomenon have used quantitative methodology where the questions asked have been preset by the researchers and the subjective experience of the patient has been minimized. Qualitative methodology was utilized in this study in order to give voice to the patients' perspectives, and contribute to the knowledge of the frameworks of meanings employed by patients. The majority of participants in this study did not perceive that they had a mental illness and they held strong beliefs regarding the usefulness of cannabis. They gave explanations for their continuing cannabis use that expanded the understanding from previous studies. These included that they sought the drug effects of cannabis use for clarity of voices, control of symptoms, to feel normal, perceived improvement in cognitive function, reduced psychological pain and increased energy. These beliefs may influence a person's adherence with treatment and their future cannabis use. This research has implications for clinical practice as clinicians may lack insight into the importance of the phenomenological beliefs of a person with schizophrenia. This lack of insight by the clinician into the phenomenological beliefs may impact on the development of a therapeutic relationship.

Entities:  

Mesh:

Year:  2008        PMID: 18666905     DOI: 10.1111/j.1447-0349.2008.00538.x

Source DB:  PubMed          Journal:  Int J Ment Health Nurs        ISSN: 1445-8330            Impact factor:   3.503


  7 in total

1.  Effects of eye dominance (left vs. right) and cannabis use on intermanual coordination and negative symptoms in schizophrenia patients.

Authors:  Inge Gorynia; Markus Schwaiger; Andreas Heinz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-05-04       Impact factor: 5.270

2.  Acute administration of Δ⁹ tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice.

Authors:  Jason Smucny; Karen E Stevens; Jason R Tregellas
Journal:  Pharmacol Biochem Behav       Date:  2014-01-10       Impact factor: 3.533

3.  Understanding how people who use illicit drugs and alcohol experience relationships with psychiatric inpatient staff.

Authors:  Emma Chorlton; Ian Smith; Sarah Amelia Jones
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-07-10       Impact factor: 4.328

Review 4.  Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders.

Authors:  Uma Suryadevara; Dawn M Bruijnzeel; Meena Nuthi; Darin A Jagnarine; Rajiv Tandon; Adriaan W Bruijnzeel
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

5.  The Association between Cannabis Product Characteristics and Symptom Relief.

Authors:  Sarah S Stith; Jacob M Vigil; Franco Brockelman; Keenan Keeling; Branden Hall
Journal:  Sci Rep       Date:  2019-02-25       Impact factor: 4.379

6.  Walking the fine line: self-reported reasons for substance use in persons with severe mental illness.

Authors:  Henning Pettersen; Torleif Ruud; Edle Ravndal; Anne Landheim
Journal:  Int J Qual Stud Health Well-being       Date:  2013-12-20

7.  Behavioral Characterization of the Effects of Cannabis Smoke and Anandamide in Rats.

Authors:  Adriaan W Bruijnzeel; Xiaoli Qi; Lidia V Guzhva; Shannon Wall; Jie V Deng; Mark S Gold; Marcelo Febo; Barry Setlow
Journal:  PLoS One       Date:  2016-04-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.